zepbound versus mounjaro

Morningstar: Lilly says Mounjaro and Zepbound sales more than doubled as stock rallied Lilly says Mounjaro and Zepbound sales more than doubled as stock rallied Healthline: Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes MarketWatch: Lilly says Mounjaro and Zepbound sales more than doubled, as stock rallies Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ... Lilly says Mounjaro and Zepbound sales more than doubled, as stock rallies Share on Pinterest Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss.